TrovaGene (TROV) has 3,274,876 shares of shorts outstanding as on August 15, 2016, with 13 days left to cover or roll them over. On Jul 29, 2016, the open interest of short positions was 3,758,333 shares. The stock has a decent trading volume of 252,332 shares daily. The marginal decrease in the short positions is by -12.9%, which amounts to -483,457 shares. Short positions are 12.1% of the available float. The short interest information was released on Wednesday Aug 24th after the market close.
TrovaGene (NASDAQ:TROV): The stock opened at $5.19 on Wednesday but the bulls could not build on the opening and the stock topped out at $5.47 for the day. The stock traded down to $5.00 during the day, due to lack of any buying support eventually closed down at $5.06 with a loss of -2.88% for the day. The stock had closed at $5.21 on the previous day. The total traded volume was 341,972 shares.
In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Trovagene, Inc., Tennant Stanley, had purchased 10,000 shares in a transaction dated on August 12, 2015. The transaction was executed at $6.06 per share with total amount equaling $60,600.
Trovagene, Inc. is a development-stage molecular diagnostic company that focuses on the development and commercialization of urine-based cell-free molecular diagnostic technology for use in disease detection and monitoring across a variety of medical disciplines. The Companys primary internal focus is to leverage its urine-based molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. Its cell-free BRAF test confirms the presence of a BRAF V600E mutation in urine DNA at levels of greater than or equal to 0.03% in comparison to the wild-type BRAF genes. Its KRAS mutation assay detects and monitors the seven commonly encountered mutations of the KRAS oncogene. Its urine-based Human Papilloma Virus (HPV) assay identifies women with high grade cervical intraepithelial neoplasia (CIN2/3).